Cell therapy is coming into its own as an effective therapeutic avenue for cancer. Into that fray in November 2019 launched Umoja Biopharma, whose unique immunotherapy approach aims to re-engineer a patient’s own immune system in vivo to attack and destroy hematologic and solid organ-based tumors.

At TFF Pharmaceuticals, our experience has offered important perspective on how strategically crafted CDMO partnerships can facilitate more efficient manufacturing and scale-up of complex modalities such as biologics.

Psychedelic medicine firm MindMed (Nasdaq: MNMD)has dosed the first patient in a Phase 2b dose-optimization trial of MM-120, a pharmaceutically optimized form of lysergic acid diethylamide (LSD).

At TFF Pharmaceuticals, our experience has offered important perspective on how strategically crafted CDMO partnerships can facilitate more efficient manufacturing and scale-up of complex modalities such as biologics.

Recent years have seen a surge of research into rarer forms of kidney disease, with drug companies, regulators, and researchers alike hunting for ways to help patients who have few options.

In what instances should organizations outsource vs. insource? Determining the right outsourcing strategy is key to limit unnecessary costs, maintain output and turnaround times, and enable continued flexibility.

THBC is selling its platelets to local hospitals, which use them to help prevent bleeding in cancer patients as well as those undergoing surgery and organ transplants.

Overall, Ashvattha’s strategy will be to prioritise functional outcomes over surrogate markers, Cleland explains. The long Covid field still lacks any standardised clinical trial endpoints, making late-stage trial design a largely uncharted territory.